phase readout
saveNCT06243354: Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation
RECRUITINGupdated 1mo ago
community read0 votes
Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd. Phase: PHASE1. Conditions: Safety, Tolerability, Efficacy
view source ↗
comments(0)
5-min edit window · permanent after that